The 10-second takeaway
For the quarter ended March 31 (Q1), PharMerica beat slightly on revenue and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue contracted and GAAP earnings per share increased significantly.
Margins grew across the board.
PharMerica logged revenue of $498.9 million. The seven analysts polled by S&P Capital IQ expected net sales of $493.6 million on the same basis. GAAP reported sales were 6.8% lower than the prior-year quarter's $535.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.30. The eight earnings estimates compiled by S&P Capital IQ predicted $0.27 per share. GAAP EPS of $0.19 for Q1 were 73% higher than the prior-year quarter's $0.11 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 14.6%, 250 basis points better than the prior-year quarter. Operating margin was 3.5%, 140 basis points better than the prior-year quarter. Net margin was 1.1%, 50 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $488.5 million. On the bottom line, the average EPS estimate is $0.31.
Next year's average estimate for revenue is $1.94 billion. The average EPS estimate is $1.20.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 125 members out of 131 rating the stock outperform, and six members rating it underperform. Among 24 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 23 give PharMerica a green thumbs-up, and one gives it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PharMerica is outperform, with an average price target of $15.25.
The healthcare investing landscape is littered with also-rans and a few major winners. Is PharMerica prepared for the future? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add PharMerica to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.